BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bär F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol 2013; 19(11): 1699-1706 [PMID: 23555158 DOI: 10.3748/wjg.v19.i11.1699] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang HH, He Y, Wang HX, Liao CL, Peng Y, Tao LJ, Zhang W, Yang HX. Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(8): 941-948 [PMID: 29491687 DOI: 10.3748/wjg.v24.i8.941] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
2 Rouiller-Braunschweig C, Fournier N, Pittet V, Dudler J, Michetti P. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients. Digestion 2017;96:220-7. [PMID: 29065423 DOI: 10.1159/000482007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Annaházi A, Molnár T. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract 2015;2015:832395. [PMID: 26199624 DOI: 10.1155/2015/832395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
4 Bayhan T, Ünal Ş, Gümrük F, Çetin M. Immune Thrombocytopenic Purpura During Maintenance Phase of Acute Lymphoblastic Leukemia: A Rare Coexistence Requiring a High Degree of Suspicion, a Case Report and Review of the Literature. Turk J Haematol 2015;32:363-6. [PMID: 25913619 DOI: 10.4274/tjh.2014.0138] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Maráková K, Piešťanský J, Mikuš P. Determination of Drugs for Crohn’s Disease Treatment in Pharmaceuticals by Capillary Electrophoresis Hyphenated with Tandem Mass Spectrometry. Chromatographia 2017;80:537-46. [DOI: 10.1007/s10337-016-3213-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Ledder O, Lemberg DA, Day AS. Thiopurine-induced pancreatitis in inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2015;9:399-403. [PMID: 25494551 DOI: 10.1586/17474124.2015.992879] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
7 Mahmoud NN, Halwani Y, Montbrun SD, Shah PM, Hedrick TL, Rashid F, Schwartz DA, Dalal RL, Kamiński JP, Zaghiyan K, Fleshner PR, Weissler JM, Fischer JP. Current management of perianal Crohn’s disease. Current Problems in Surgery 2017;54:262-98. [DOI: 10.1067/j.cpsurg.2017.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Klag T, Goetz M, Stange EF, Wehkamp J. Medical Therapy of Perianal Crohn’s Disease. Viszeralmedizin. 2015;31:265-272. [PMID: 26557835 DOI: 10.1159/000434664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016;10:812-820. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
10 Ho CC, Fong WY, Lee YH, Poon WT. Novel Tetra-Primer ARMS-PCR Assays for Thiopurine Intolerance Susceptibility Mutations NUDT15 c.415C>T and TPMT c.719A>G (TPMT*3C) in East Asians. Genes (Basel) 2017;8:E285. [PMID: 29065511 DOI: 10.3390/genes8100285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
12 Carvalho ATP, Esberard BC, Fróes RSB, Rapozo DCM, Grinman AB, Simão TA, Santos JCVC, Carneiro AJV, Ribeiro-Pinto LF, Souza HSP. Thiopurine-methyltransferase variants in inflammatory bowel disease: Prevalence and toxicity in Brazilian patients. World J Gastroenterol 2014; 20(12): 3327-3334 [PMID: 24696613 DOI: 10.3748/wjg.v20.i12.3327] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
13 Guerra Romero A, Pérez Calle JL, López Serrano P. Submaxilitis aguda secundaria a la toma de azatioprina en paciente con enfermedad de Crohn. Gastroenterología y Hepatología 2018;41:570-1. [DOI: 10.1016/j.gastrohep.2017.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
14 Heerasing NM, Ng JF, Dowling D. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine? Intern Med J 2016;46:465-9. [PMID: 26425841 DOI: 10.1111/imj.12915] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
15 Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 [PMID: 33178391 DOI: 10.4252/wjsc.v12.i10.1050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Srinath A, Young E, Szigethy E. Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside. Inflamm Bowel Dis 2014;20:2433-49. [PMID: 25208108 DOI: 10.1097/MIB.0000000000000170] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
17 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Reference Citation Analysis]
18 Adegbola SO, Pisani A, Sahnan K, Tozer P, Ellul P, Warusavitarne J. Medical and surgical management of perianal Crohn's disease. Ann Gastroenterol 2018;31:129-39. [PMID: 29507460 DOI: 10.20524/aog.2018.0236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Srinath AI, Gupta N, Husain SZ. Probing the association of pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:465-475. [PMID: 26535870 DOI: 10.1097/mib.0000000000000611] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
20 Karaahmet F, Akinci H, Ayte R, Hamamci M, Coskun Y, Yuksel I. Tremor as dose dependent side-effect of azathioprine in remission patient with ileal Crohn's disease. Journal of Crohn's and Colitis 2013;7:e404. [DOI: 10.1016/j.crohns.2013.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
21 Leung G, Papademetriou M, Chang S, Arena F, Katz S. Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. Curr Treat Options Gastro 2016;14:507-34. [DOI: 10.1007/s11938-016-0109-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Ruel NM, Nguyen KH, Vilas G, Hammond JR. Characterization of 6-Mercaptopurine Transport by the SLC43A3-Encoded Nucleobase Transporter. Mol Pharmacol 2019;95:584-96. [DOI: 10.1124/mol.118.114389] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Movva R, Haywood A, Khan SA, Florin TH, Oancea I. Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?: Thioguanine treatment in IBD. Journal of Digestive Diseases 2017;18:529-36. [DOI: 10.1111/1751-2980.12536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Kamp K, Holmstrom A, Luo Z, Wyatt G, Given B. Factors Influencing Received Social Support Among Emerging Adults With Inflammatory Bowel Disease: A Cross-Sectional Study. Gastroenterol Nurs 2020;43:429-39. [PMID: 33055542 DOI: 10.1097/SGA.0000000000000483] [Reference Citation Analysis]
25 Costrini NV. Clearing of the Clouds in Inflammatory Bowel Disease Management. Dig Dis Sci 2020;65:3411-7. [PMID: 33009978 DOI: 10.1007/s10620-020-06635-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Iizuka M, Etou T, Kumagai M, Matsuoka A, Numata Y, Sagara S. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. Intern Med. 2017;56:2705-2710. [PMID: 28924114 DOI: 10.2169/internalmedicine.8428-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: Safety issues. World J Gastrointest Pharmacol Ther 2014; 5(2): 63-76 [PMID: 24868487 DOI: 10.4292/wjgpt.v5.i2.63] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
28 Maráková K, Piešťanský J, Zelinková Z, Mikuš P. Capillary Electrophoresis Hyphenated with Mass Spectrometry for Determination of Inflammatory Bowel Disease Drugs in Clinical Urine Samples. Molecules 2017;22:E1973. [PMID: 29140288 DOI: 10.3390/molecules22111973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kummen M, Schrumpf E, Boberg KM. Liver abnormalities in bowel diseases. Best Pract Res Clin Gastroenterol. 2013;27:531-542. [PMID: 24090940 DOI: 10.1016/j.bpg.2013.06.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
30 Pastor-Anglada M, Pérez-Torras S. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol 2015;6:13. [PMID: 25713533 DOI: 10.3389/fphar.2015.00013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]